Literature DB >> 12645805

Sarcoidosis after use of interferon for chronic hepatitis C: report of a case and review of the literature.

V Tahan1, F Ozseker, D Guneylioglu, A Baran, R Ozaras, A Mert, A C Ucisik, T Cagatay, D Yilmazbayhan, H Senturk.   

Abstract

Although interferon has not been classified in the pathogenesis of sarcoidosis, it may rarely lead to this disease during treatment of chronic hepatitis C. The case of a 36-year-old woman with chronic hepatitis C who developed sarcoidosis within 10 weeks of treatment with recombinant interferon-alpha2a and ribavirin is described and all seven similar cases published in English from 1989 to 2001 are discussed.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12645805     DOI： 10.1023/a:1021759120428

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


  17 in total

1.  Sarcoidosis and IFN-alpha treatment.

Authors:  N J Vander Els; H Gerdes
Journal:  Chest       Date:  2000-01       Impact factor: 9.410

2.  Cutaneous sarcoid foreign body granulomas developing in sites of previous skin injury after systemic interferon-alpha treatment for chronic hepatitis C.

Authors:  B Eberlein-König; R Hein; D Abeck; R Engst; J Ring
Journal:  Br J Dermatol       Date:  1999-02       Impact factor: 9.302

Review 3.  Hepatitis C virus infection.

Authors:  G M Lauer; B D Walker
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

Review 4.  Sarcoidosis after interferon therapy for chronic active hepatitis C.

Authors:  H Teragawa; T Hondo; K Takahashi; H Watanabe; H Ohe; N Hattori; Y Watanabe; H Amano; F Hino; M Ohbayashi; T Urushihara; S Yonehara
Journal:  Intern Med       Date:  1996-01       Impact factor: 1.271

5.  Interstitial pneumonia caused by interferon-alpha in chronic myelogenous leukemia.

Authors:  Y Yufu; S Yamashita; J Nishimura; H Nawata; J Hirata
Journal:  Am J Hematol       Date:  1994-11       Impact factor: 10.047

6.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

7.  Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response.

Authors:  Q Ning; D Brown; J Parodo; M Cattral; R Gorczynski; E Cole; L Fung; J W Ding; M F Liu; O Rotstein; M J Phillips; G Levy
Journal:  J Immunol       Date:  1998-04-01       Impact factor: 5.422

8.  Spontaneous release of interleukin-2 by lung T lymphocytes in active pulmonary sarcoidosis.

Authors:  P Pinkston; P B Bitterman; R G Crystal
Journal:  N Engl J Med       Date:  1983-04-07       Impact factor: 91.245

9.  Recurrence of sarcoidosis following interferon alpha therapy for chronic hepatitis C.

Authors:  M Nakajima; Y Kubota; N Miyashita; Y Niki; T Matsushima; T Manabe
Journal:  Intern Med       Date:  1996-05       Impact factor: 1.271

10.  Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C.

Authors:  R M Hoffmann; M C Jung; R Motz; C Gössl; H P Emslander; R Zachoval; G R Pape
Journal:  J Hepatol       Date:  1998-06       Impact factor: 25.083
View more
  10 in total

Review 1.  Hepatic sarcoidosis associated with pegylated interferon alfa therapy for chronic hepatitis C: case report and review of literature.

Authors:  Mahathi Adla; Kathy K Downey; Jawad Ahmad
Journal:  Dig Dis Sci       Date:  2008-03-05       Impact factor: 3.199

Review 2.  Development of sarcoidosis following completion of treatment for hepatitis C with pegylated interferon-{alpha}2a and ribavirin: a case report and literature review.

Authors:  Albéric-Rembrandt Gayet; Patrick Plaisance; Jean-François Bergmann; Stéphane Mouly
Journal:  Clin Med Res       Date:  2010-09-17

3.  Prevalence of hepatic granulomas in chronic hepatitis B.

Authors:  Veysel Tahan; Resat Ozaras; Nadir Lacevic; Ercan Ozden; Mucahit Yemisen; Osman Ozdogan; Ali Mert; Fehmi Tabak; Erol Avsar; Cigdem Ataizi Celikel; Gulsen Ozbay; Cem Kalayci; Hakan Senturk; Nurdan Tozun
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

4.  Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C.

Authors:  R Rodríguez-Lojo; M Almagro; J M Barja; F Piñeyro; L Pérez-Varela; J Del Pozo; M T Yebra-Pimentel; E Fonseca
Journal:  Dermatol Res Pract       Date:  2010-04-29

5.  Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C.

Authors:  Elson Vidal Martins; Ana Karla Gaburri; Debora Gaburri; Angelo Sementilli
Journal:  Case Rep Gastroenterol       Date:  2009-11-21

6.  [Cutaneous sarcoidosis after treatment with interferon for hepatitis C: A not entirely rare but often overlooked reaction].

Authors:  A Waltschew
Journal:  Pathologe       Date:  2016-03       Impact factor: 1.011

7.  Pegylated Interferon-Induced Sarcoidosis Presenting With Anterior Uveitis in a Patient with Chronic Hepatitis C - Case Report.

Authors:  A M Kamal; P Mitruț; C K Kamal; D O Alexandru; A Tica
Journal:  Curr Health Sci J       Date:  2015-12-22

8.  Severe interstitial pneumonitis secondary to pegylated interferon alpha-2b and ribavirin treatment of hepatitis C infection.

Authors:  Valentin Fuhrmann; Ludwig Kramer; Edith Bauer; Hermann Laferl; Gerhard Tucek; Gerhard Dekan; Peter Schenk
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

Review 9.  Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature.

Authors:  Serena Slavenburg; Yvonne F Heijdra; Joost P H Drenth
Journal:  Dig Dis Sci       Date:  2009-04-28       Impact factor: 3.199

10.  Concurrent acute interstitial pneumonia and pulmonary embolism during treatment with peginterferon alpha-2a and ribavirin in a patient with hepatitis C.

Authors:  Hikmet Coban; Mehmet Yahyaoglu; M Bülent Vatan
Journal:  Indian J Pharmacol       Date:  2014 Jul-Aug       Impact factor: 1.200
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.